109 related articles for article (PubMed ID: 24792642)
1. Comprehensive exploration of autoantibody in Behçet's disease: a novel autoantibody to claudin-1, an essential protein for tight junctions, is identified.
Morishima A; Hirano T; Nishikawa H; Nakai K; Sakaguchi S; Kumanogoh A
Joint Bone Spine; 2014 Dec; 81(6):546-8. PubMed ID: 24792642
[No Abstract] [Full Text] [Related]
2. Autoantibodies against oxidatively modified low-density lipoprotein in patients with Behçet's disease.
Orem A; Cimşit G; Değer O; Vanizor B; Karahan SC
Dermatology; 1999; 198(3):243-6. PubMed ID: 10393445
[TBL] [Abstract][Full Text] [Related]
3. Low serum mannose-binding lectin levels in Behçet's disease.
Inanc N; Birtas E; Yavuz S; Ergun T; Direskeneli H
Adv Exp Med Biol; 2003; 528():287-9. PubMed ID: 12918709
[No Abstract] [Full Text] [Related]
4. Circulating immune complexome analysis identified anti-tubulin-α-1c as an inflammation associated autoantibody with promising diagnostic value for Behcet's Disease.
Cheng Y; Zhao X; Chen Y; Li Y; Jia R; Zhu L; Huang C; Sun X; Deng H; Li Z
PLoS One; 2018; 13(6):e0199047. PubMed ID: 29902281
[TBL] [Abstract][Full Text] [Related]
5. Carbonic anhydrase I and II autoantibodies in Behçet's disease.
Mentese A; Alver A; Demir S; Sumer A; Ozer Yaman S; Karkucak M; Aydin Capkin A; Us Altay D; Turan I
Acta Reumatol Port; 2017; 42(1):26-31. PubMed ID: 28198796
[TBL] [Abstract][Full Text] [Related]
6. Antiannexin V autoantibody in thrombophilic Behçet's disease.
Aslan H; Pay S; Gok F; Baykal Y; Yilmaz MI; Sengul A; Aydin HI
Rheumatol Int; 2004 Mar; 24(2):77-9. PubMed ID: 14658002
[TBL] [Abstract][Full Text] [Related]
7. Antineutrophil cytoplasmic autoantibody in two patients with Behçet's disease.
Baleva M; Kolarov Z; Nikolov K
Nephrol Dial Transplant; 1994; 9(7):876. PubMed ID: 7818712
[No Abstract] [Full Text] [Related]
8. Identification of HnRNP-A2/B1 as a target antigen of anti-endothelial cell IgA antibody in Behçet's disease.
Cho SB; Ahn KJ; Kim DH; Zheng Z; Cho S; Kang SW; Lee JH; Park YB; Lee KH; Bang D
J Invest Dermatol; 2012 Mar; 132(3 Pt 1):601-8. PubMed ID: 22205302
[TBL] [Abstract][Full Text] [Related]
9. Serum levels of Th2 cytokines IL-4 and IL-10 in Behçet's disease.
Mantaş C; Direskeneli H; Ekşioglu-Demiralp E; Akoglu T
J Rheumatol; 1999 Feb; 26(2):510-2. PubMed ID: 9972999
[No Abstract] [Full Text] [Related]
10. Serum soluble CD30 levels in Behçet's disease.
Düzgün N; Ayaslioglu E; Tutkak H
Clin Exp Rheumatol; 2004; 22(4 Suppl 34):S17-20. PubMed ID: 15515777
[TBL] [Abstract][Full Text] [Related]
11. Identification of heat shock protein 27 as a novel autoantigen of Behçet's disease.
Chen P; Shi L; Jiang Y; Ji Y; Yan H; Sun S; Xun Y; Chen G; Wang X; Chen W; Du H
Biochem Biophys Res Commun; 2015 Jan; 456(4):866-71. PubMed ID: 25529454
[TBL] [Abstract][Full Text] [Related]
12. Antikinectin autoantibody in Behçet's disease and several other autoimmune connective tissue diseases.
Feng XG; Ye S; Lu Y; Xu XJ; Gu YY; Shen N; Ye P; Cheng FP; Wang AM; Chen SL
Clin Exp Rheumatol; 2007; 25(4 Suppl 45):S80-5. PubMed ID: 17949557
[TBL] [Abstract][Full Text] [Related]
13. [A study of antiendothelial cell antibodies in Behcet's disease].
Zheng WJ; Zhao Y; Tang FL; Dong Y
Zhonghua Nei Ke Za Zhi; 2005 Dec; 44(12):910-3. PubMed ID: 16409728
[TBL] [Abstract][Full Text] [Related]
14. Serum anti-lysozyme is associated with disease activity of Behçet's disease.
Park JS; Kang MI; Ha YJ; Song JJ; Park YB; Lee SK; Lee SW
Int J Rheum Dis; 2017 Feb; 20(2):261-268. PubMed ID: 26890818
[TBL] [Abstract][Full Text] [Related]
15. The evaluation of autoantibodies against oxidatively modified low-density lipoprotein (LDL), susceptibility of LDL to oxidation, serum lipids and lipid hydroperoxide levels, total antioxidant status, antioxidant enzyme activities, and endothelial dysfunction in patients with Behçet's disease.
Orem A; Yandi YE; Vanizor B; Cimşit G; Uydu HA; Malkoç M
Clin Biochem; 2002 May; 35(3):217-24. PubMed ID: 12074830
[TBL] [Abstract][Full Text] [Related]
16. Identification of kinectin as a novel Behçet's disease autoantigen.
Lu Y; Ye P; Chen SL; Tan EM; Chan EK
Arthritis Res Ther; 2005; 7(5):R1133-9. PubMed ID: 16207330
[TBL] [Abstract][Full Text] [Related]
17. Anti-alpha-enolase antibodies in Behçet's disease: a marker of mucocutaneous and articular disease activity?
Prado LL; Goncalves CR; Viana VT; Saad CGS; Bonfa E
Clin Exp Rheumatol; 2018; 36(6 Suppl 115):28-32. PubMed ID: 29465373
[TBL] [Abstract][Full Text] [Related]
18. Synovial histopathology of behçet's syndrome.
Gibson T; Laurent R; Highton J; Wilton M; Dyson M; Millis R
Ann Rheum Dis; 1981 Aug; 40(4):376-81. PubMed ID: 7020613
[TBL] [Abstract][Full Text] [Related]
19. Anti-cyclic citrullinated peptide antibodies in rheumatoid arthritis and Behçet's disease.
Koca SS; Akbulut H; Dag S; Artas H; Isik A
Tohoku J Exp Med; 2007 Dec; 213(4):297-304. PubMed ID: 18075233
[TBL] [Abstract][Full Text] [Related]
20. Antibody to intermediate filaments of the cytoskeleton in patients with Behçet's disease.
Akoğlu T; Kozakoğlu H; Akoğlu E
Clin Immunol Immunopathol; 1986 Dec; 41(3):427-32. PubMed ID: 3780056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
